Interleukin-1 Receptor Antagonist (IL-1RA) (ANAKINRA) IN SEVERE SYSTEMIC-ONSET JUVENILE IDIOPATHIC ARTHRITIS

Clinical Trial ID NCT00339157

PubWeight™ 5.96‹?›

🔗 Visit the ClinicalTrials.gov page for NCT00339157

Top papers

Rank Title Journal Year PubWeight™‹?›
1 A multicentre, randomised, double-blind, placebo-controlled trial with the interleukin-1 receptor antagonist anakinra in patients with systemic-onset juvenile idiopathic arthritis (ANAJIS trial). Ann Rheum Dis 2010 2.22
2 RNA recognition by human TLR8 can lead to autoimmune inflammation. J Exp Med 2013 1.64
3 Recent developments in anti-rheumatic drugs in pediatrics: treatment of juvenile idiopathic arthritis. Arthritis Res Ther 2009 1.26
4 Cryopyrin-associated periodic syndrome: an update on diagnosis and treatment response. Curr Allergy Asthma Rep 2011 0.97
Next 100